Pure Global AI
NCT06391905Not yet recruiting

PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS

Guangdong Provincial People's HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Colorectal Cancer
Drug/Device/Intervention
PCSK9 inhibitor in combination with standard advanced first-line regimen group
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Guangdong Provincial People's Hospital
Timeline & enrollment
Phase
Phase 2
Start date
May 06, 2024
End date
May 06, 2028
Enrollment
60 participants
Primary outcome

Objective response rateObjective response rate (ORR)

Summary

The purpose of this study is to preliminarily observe the efficacy and safety of PCSK9
 inhibitors in combination with standard advanced first-line regimens in the treatment of
 advanced colorectal cancer with pMMR/MSS.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06391905
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06391905 through Pure Global AI's free database. This Phase 2 trial is sponsored by Guangdong Provincial People's Hospital and is currently Not yet recruiting. The study focuses on Colorectal Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.